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background:  Guidelines advocate dual antiplatelet therapy (DAPT) for ACS, but few data exist regarding differential response to DAPT among ACS 
patients taking clopidogrel prior to index ACS events vs those not previously on clopidogrel.
methods: Patients with non-ST-elevation ACS were managed medically without revascularization in the TRILOGY ACS trial and stratified by 
prerandomization clopidogrel use (none; clopidogrel started ≤72 h of admission; prior clopidogrel continued until randomization). We analyzed 
differences in ischemic outcomes and how clopidogrel use modified the randomized treatment effect of prasugrel vs clopidogrel among the 3 
groups.
results: Of 9,325 patients, 398 (4%) had no prior clopidogrel treatment; 6,513 (70%) received clopidogrel in-hospital before randomization; and 
2,414 (26%) were on prior clopidogrel continued to randomization. Those started on clopidogrel in-hospital were older, less likely to be male, were 
diabetic, or had a history of prior cardiovascular (CV) events and had a lower rate of CV death/MI/stroke through 30 mos (HR 0.8; 95% CI 0.7-0.9; 
P=0.002) compared with patients on prior clopidogrel. Prior clopidogrel use did not modify the randomized treatment effect in the 3 groups (all 
interaction P > 0.05).
Conclusion: These findings suggest that chronic DAPT use may be associated with a higher CV risk profile and comorbidities, but not with lower 
long-term CV event rates in medically-managed ACS patients, and may warrant further study. 
Table. Baseline Characteristics and Observed Rate of CV Outcomes Among the 3 Groups
No prior clopidogrel use
(n=398)
Clopidogrel started in-hospital ≤72 h
(n=6,513)
Chronic clopidogrel
(n=2,414)
Global P value
Median age, y (25th, 75th) 65 (59, 72) 66 (60, 74) 64 (56, 72) <0.001
Female sex, % 42.2 40.5 35.0 <0.001
Diabetes mellitus, % 36.4 37.0 41.1 0.001
Current/recent smoking, % 19.1 21.4 16.1 <0.001
Prior MI, % 41.9 35.5 63.8 <0.001
Prior PCI, % 23.9 16.7 52.1 <0.001
Prior CABG, % 17.1 13.5 21.2 <0.001
Prior PAD, % 6.5 6.4 10.4 <0.001
Prior heart failure, % 22.5 14.7 24.5 <0.001
CV death/MI/stroke through 30 months, % 20.1 18.2 20.8 -
CABG, coronary artery bypass graft; CV, cardiovascular; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary 
intervention
